Filing Details
- Accession Number:
- 0000899243-18-004480
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-20 06:07:30
- Reporting Period:
- 2018-01-02
- Accepted Time:
- 2018-02-20 06:07:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1160308 | Savara Inc | SVRA | Pharmaceutical Preparations (2834) | 841318182 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1408498 | L David Lowrance | 900 S. Capital Of Texas Highway, Suite 150 Austin TX 78746 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-01-02 | 31,894 | $1.51 | 33,994 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-01-02 | 3,239 | $15.06 | 30,755 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2018-02-15 | 4,936 | $12.70 | 25,819 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-15 | 2,064 | $13.30 | 23,755 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2018-01-02 | 31,894 | $0.00 | 31,894 | $1.51 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 95,684 | 2026-10-25 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 for February 15, 2018 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2017.
- The price reported is a weighted average sale price. The sale prices ranged from $12.31 to $12.96.
- The price reported is a weighted average sale price. The sale prices ranged from $13.00 to $13.71. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The shares subject to the option vest and become exercisable in sixteen equal quarterly installments beginning on February 1, 2017.
Billionaire Hedge Funds
